Borneol exerts its antipruritic effects by inhibiting TRPA1 and activating TRPM8.

Borneol is a long-established traditional Chinese medicine that has been found to be effective in treating pain and itchy skin. However, whether borneol has a therapeutic effect on chronic itch and its related mechanisms remain unclear. To investigate the antipruritic effect of borneol and its molecular mechanism. DrugBAN framework and molecular docking were applied to predict the targets of borneol, and the calcium imaging or patch-clamp recording analysis were used to detect the effects of borneol on TRPA1, TRPM8 or TRPV3 channels in HEK293T cells. In addition, various mouse models of acute itch and chronic itch were established to evaluate the antipruritic effects of borneol on C5 7BL /6J mice. Then, the borneol-induced pruritic relief was further investigated in Trpa1 −/− , Trpm8 −/− , or Trpa1 −/− / Trpm8 −/− mice. The effects of borneol on the activation of TRPM8 and the inhibition of TRPA1 were also measured in dorsal root ganglia neurons of wild-type (WT), Trpm8 −/− and Trpv1 −/− mice. Lastly, a randomized, double-blind study of adult patients was conducted to evaluate the clinical antipruritic effect of borneol. TRPA1, TRPV3 and TRPM8 are the potential targets of borneol according to the results of DrugBAN algorithm and molecular docking. Calcium imaging and patch-clamp recording analysis demonstrated that borneol activates TRPM8 channel-induced cell excitability and inhibits TRPA1 channel-mediated cell excitability in transfected HEK293T cells. Animal behavior analysis showed that borneol can significantly reduce acute and chronic itch behavior in C5 7BL /6J mice, but this effect was eliminated in Trpa1 −/− , Trpm8 −/− mice, or at least in Trpa1 −/− /Trpm8 −/− mice. Borneol elicits TRPM8 channel induced [Ca2+] i responses but inhibits AITC or SADBE-induced activation of TRPA1 channels in dorsal root ganglia neurons of WT and Trpv1 −/− mice, respectively. Furthermore, the clinical results indicated that borneol could reduce itching symptoms in patients and its efficacy is similar to that of menthol. Borneol has therapeutic effects on multiple pruritus models in mice and patients with chronic itch, and the mechanism may be through inhibiting TRPA1 and activating TRPM8. [Display omitted] • The clinical trial provide evidence that borneol could reduce chronic itch in patients with an efficiency similar to menthol. • The DrugBAN algorithm were applied and predicted TRPA1, TRPM8 and TRPV3 as the targets of borneol. • Borneol could relieve acute and chronic itch through inhibiting TRPA1 and activing TRPM8. [ABSTRACT FROM AUTHOR]